Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 12/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 12/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806067 | 0.91 | LPAR1 (0.43) | LPAR1LPAR5LMNAGAAKMT2A | |
| SCHEMBL6802925 | 0.89 | LPAR1 (0.46) | LPAR1LPAR5CA12CA1CA2 | |
| SCHEMBL6540096 | 0.84 | LPAR1 (0.54) | LPAR1LPAR5LMNAGAACA12 | |
| SCHEMBL6540868 | 0.81 | LPAR1 (0.55) | LPAR1LPAR5CA12CA1CA2 | |
| SCHEMBL6799225 | 0.78 | LPAR1 (0.43) | LPAR1LPAR5LMNAGAAKMT2A | |
| SCHEMBL17267848 | 0.78 | LMNA (0.68) | LMNAGAAKMT2A | |
| SCHEMBL6541221 | 0.78 | LPAR1 (0.52) | LPAR1LPAR5CA12CA1CA2 | |
| SCHEMBL6676179 | 0.78 | LMNA (0.45) | LMNAGAAKMT2ACA12CA1 | |
| SCHEMBL6798502 | 0.77 | CA12 (0.55) | CA12CA1CA2CA4LIMK1 | |
| SCHEMBL6802456 | 0.76 | LPAR1 (0.47) | LPAR1LPAR5LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | LPAR1 1110/4885LPAR5 1485/4885LMNA 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.